Jak3 - Janus kinase 3 Gene

Rattus norvegicus

Also known as RATJAK3

Gene ID: 25326 | Gene type: protein coding

About Jak3

Primary_assembly 16: 18,386,405-18,398,536 forward strand.mRatBN7.2:CM026989.1

This gene has 1 transcript (splice variant), 103 orthologues, 32 paralogues and is associated with 39 phenotypes. Biased expression in Spleen (RPKM 69.2), Thymus (RPKM 61.) and 8 other tissues.

Summary

Predicted to enable protein Phosphatase binding activity and protein tyrosine kinase activity. Involved in several processes, including positive regulation of activated T cell proliferation; positive regulation of cytosolic calcium ion concentration; and positive regulation of nitric-oxide synthase biosynthetic process. Located in cytoplasm. Biomarker of tongue squamous cell carcinoma. Human ortholog(s) of this gene implicated in T-cell acute lymphoblastic leukemia; acute megakaryocytic leukemia; adult T-cell leukemia; and juvenile myelomonocytic leukemia. Orthologous to human JAK3 (Janus kinase 3). [provided by Alliance of Genome Resources, Apr 2022]

Jak3 Products(1)

mRNA	Protein	Name
NM_012855.2	NP_036987.2	tyrosine-protein kinase JAK3

Jak3 Protein Structure

FERM_F1

FERM_F2

FERM_C_JAK3

SH2

PKc_like

0
200
400
600
800
1000
1100 a.a.

Protein Preferred Names

Protein Names

tyrosine-protein kinase JAK3

JAK-3

Janus kinase 3, protein-tyrosine kinase

Related Agents

Approval

Bioactive Molecules (17)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-50856	Ruxolitinib	Inhibitor	99.99%	Yes
HY-40354	Tofacitinib	Inhibitor	99.99%	Yes
HY-15315	Baricitinib	Inhibitor	99.97%	Yes
HY-19569	Upadacitinib	Inhibitor	99.98%	Yes
HY-50858	Ruxolitinib phosphate	Inhibitor	99.98%	Yes
HY-16379	Pacritinib	Inhibitor	99.93%	Yes
HY-40354A	Tofacitinib citrate	Inhibitor	99.98%	Yes
HY-18300	Filgotinib	Inhibitor	99.68%	Yes
HY-19568	Peficitinib	Inhibitor	99.43%	Yes
HY-15315A	Baricitinib phosphate	Inhibitor	99.91%	Yes
HY-109053	Delgocitinib	Inhibitor	99.87%	Unkown
HY-13577A	Oclacitinib maleate	Inhibitor	99.63%	Unkown
HY-13577	Oclacitinib	Inhibitor	99.23%	Unkown
HY-19569A	Upadacitinib tartrate tetrahydrate	Inhibitor	/	Unkown
HY-16379A	Pacritinib hydrochloride	Inhibitor	/	Unkown
HY-18300A	Filgotinib maleate	Inhibitor	/	Unkown
HY-50859	Ruxolitinib sulfate	Inhibitor	/	Unkown

Clinical Phase

Bioactive Molecules (17)

Cat. No.	Product Name	Effect	Purity	Phase
HY-100754	Ritlecitinib	Inhibitor	99.98%	Phase 3
HY-10961	Momelotinib	Inhibitor	99.37%	Phase 3
HY-15999	Cerdulatinib	Inhibitor	98.96%	Phase 3
HY-12469	Decernotinib	Inhibitor	99.67%	Phase 3
HY-10962	Momelotinib sulfate	Inhibitor	98.06%	Phase 3
HY-112724	Ivarmacitinib	Inhibitor	99.82%	Phase 3
HY-15999A	Cerdulatinib hydrochloride	Inhibitor	99.89%	Phase 3
HY-10963	Momelotinib Mesylate	Inhibitor	/	Phase 3
HY-50514	AT9283	Inhibitor	99.70%	Phase 2
HY-13034	Gandotinib	Inhibitor	99.82%	Phase 2
HY-15270	BMS-911543	Inhibitor	98.53%	Phase 2
HY-112708A	Brepocitinib P-Tosylate	Inhibitor	99.86%	Phase 2
HY-19631A	Ilginatinib	Inhibitor	99.53%	Phase 2
HY-112708	Brepocitinib	Inhibitor	98.64%	Phase 2
HY-19631B	Ilginatinib hydrochloride	Inhibitor	≥98.0%	Phase 2
HY-19631	Ilginatinib maleate	Inhibitor	99.87%	Phase 2
HY-13775	XL019	Inhibitor	≥98.0%	Phase 1

Pre-clinical Phase

Bioactive Molecules (57)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-14435	Pyridone 6	Inhibitor	98.13%	Unkown
HY-10410	TG101209	Inhibitor	99.22%	Unkown
HY-15343	CEP-33779	Inhibitor	99.23%	Unkown
HY-10411	AZ960	Inhibitor	97.15%	Unkown
HY-15508	JANEX-1	Inhibitor	99.84%	Unkown
HY-100895	SAR-20347	Inhibitor	97.12%	Unkown
HY-131140	BD750	Inhibitor	99.10%	Unkown
HY-13895	WHI-P154	Inhibitor	99.39%	Unkown
HY-145696	SJ10542	Inhibitor	99.92%	Unkown
HY-14722	NVP-BSK805	Inhibitor	99.89%	Unkown
HY-12589	ZM39923 hydrochloride	Inhibitor	98.19%	Unkown
HY-101976	JAK3-IN-6	Inhibitor	99.90%	Unkown
HY-14722A	NVP-BSK805 dihydrochloride	Inhibitor	99.36%	Unkown
HY-151262	JAK-IN-23	Inhibitor	98.90%	Unkown
HY-130247	JAK2/FLT3-IN-1	Inhibitor	99.79%	Unkown
HY-102046	FM-381	Inhibitor	99.58%	Unkown
HY-131906	JAK2-IN-7	Inhibitor	99.15%	Unkown
HY-150023	BI-1622	Inhibitor	98.97%	Unkown
HY-130247A	JAK2/FLT3-IN-1 TFA	Inhibitor	99.77%	Unkown
HY-108264	TCS 21311	Inhibitor	99.18%	Unkown
HY-139423	JAK1-IN-8	Inhibitor	≥95.0%	Unkown
HY-120469	2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	Inhibitor	98.78%	Unkown
HY-11067	WHI-P97	Inhibitor	99.70%	Unkown
HY-19544	JAK3-IN-1	Inhibitor	99.23%	Unkown
HY-100754B	(2R,5S)-Ritlecitinib	Inhibitor	98.83%	Unkown
HY-13961	GLPG0634 analog	Inhibitor	98.58%	Unkown
HY-111750	JAK-IN-3	Inhibitor	98.92%	Unkown
HY-119935	JAK3 covalent inhibitor-1	Inhibitor	/	Unkown
HY-152080	TUL01101	Inhibitor	/	Unkown
HY-146727	JAK3-IN-11	Inhibitor	/	Unkown
HY-151285	JAK-2/3-IN-3	Inhibitor	/	Unkown
HY-161354	JAK3 covalent inhibitor-2	Inhibitor	/	Unkown
HY-150720	TYK2-IN-12	Inhibitor	/	Unkown
HY-151259	TK4b	Inhibitor	/	Unkown
HY-151258	TK4g	Inhibitor	/	Unkown
HY-149283	JAK/HDAC-IN-2	Inhibitor	/	Unkown
HY-143885	JAK1/TYK2-IN-3	Inhibitor	/	Unkown
HY-100849	JAK 3i	Inhibitor	/	Unkown
HY-147741	DPPY	Inhibitor	/	Unkown
HY-147975	JAK3-IN-12	Inhibitor	/	Unkown
HY-151256	JAK-2/3-IN-2	Inhibitor	/	Unkown
HY-10652	JAK-2/3-IN-1	Inhibitor	/	Unkown
HY-131014	FM-479		/	Unkown
HY-155951	JAK3-IN-14	Inhibitor	99.32%	Unkown
HY-153440	JAK-IN-25	Inhibitor	98.44%	Unkown
HY-133747	JAK3-IN-9	Inhibitor	/	Unkown
HY-154994	JAK-IN-30	Inhibitor	/	Unkown
HY-157121	JAK-IN-34	Inhibitor	/	Unkown
HY-147754	JAK3/BTK-IN-6	Inhibitor	/	Unkown
HY-149296	JAK1-IN-12	Inhibitor	/	Unkown
HY-108342	PF-00956980	Inhibitor	/	Unkown
HY-143444	JAK-IN-20	Inhibitor	/	Unkown
HY-147742	Thi-DPPY	Inhibitor	/	Unkown
HY-123099	MS-1020	Inhibitor	/	Unkown
HY-12589A	ZM39923	Inhibitor	/	Unkown
HY-10058	AT9283 lactic acid	Inhibitor	/	Unkown
HY-U00390	JAK3-IN-7	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Jak3	NCBI	NCBI:3718

Name
Email *

	Sorry, but the email address you supplied was invalid.